Your Messages Inbox
Your Article Summary
See Latest ArticlesKing Announces Commercial Availability of Embeda™
King Pharmaceuticals, 09/22/09
King Pharmaceuticals, Inc. announced a true milestone as it marks the first commercial availability for EMBEDA™ Extended Release Capsules, a long–acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around–the–clock opioid analgesic is needed for an extended period of time. EMBEDA™ is the first U.S. Food and Drug Administration (FDA)–approved long–acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
Allos Therapeutics, 12/01/09
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
Cell Therapeutics, 12/01/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor